COMPASS Pathways (CMPS) Competitors $4.41 -0.04 (-0.90%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CMPS vs. SAGE, MGNX, RPTX, ARQT, CALT, RCKT, ANIP, ARDX, MESO, and AVDLShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Sage Therapeutics (SAGE), MacroGenics (MGNX), Repare Therapeutics (RPTX), Arcutis Biotherapeutics (ARQT), Calliditas Therapeutics AB (publ) (CALT), Rocket Pharmaceuticals (RCKT), ANI Pharmaceuticals (ANIP), Ardelyx (ARDX), Mesoblast (MESO), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Sage Therapeutics MacroGenics Repare Therapeutics Arcutis Biotherapeutics Calliditas Therapeutics AB (publ) Rocket Pharmaceuticals ANI Pharmaceuticals Ardelyx Mesoblast Avadel Pharmaceuticals Sage Therapeutics (NASDAQ:SAGE) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Which has higher valuation and earnings, SAGE or CMPS? COMPASS Pathways has lower revenue, but higher earnings than Sage Therapeutics. COMPASS Pathways is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$106.40M2.97-$541.49M-$5.58-0.93COMPASS PathwaysN/AN/A-$118.46M-$2.20-2.00 Do institutionals and insiders hold more shares of SAGE or CMPS? 99.2% of Sage Therapeutics shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in SAGE or CMPS? Sage Therapeutics received 571 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 80.00% of users gave COMPASS Pathways an outperform vote while only 65.46% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformSage TherapeuticsOutperform Votes63165.46% Underperform Votes33334.54% COMPASS PathwaysOutperform Votes6080.00% Underperform Votes1520.00% Is SAGE or CMPS more profitable? COMPASS Pathways has a net margin of 0.00% compared to Sage Therapeutics' net margin of -317.29%. Sage Therapeutics' return on equity of -50.29% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-317.29% -50.29% -45.48% COMPASS Pathways N/A -63.85%-51.97% Does the media prefer SAGE or CMPS? In the previous week, Sage Therapeutics had 15 more articles in the media than COMPASS Pathways. MarketBeat recorded 17 mentions for Sage Therapeutics and 2 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.43 beat Sage Therapeutics' score of -0.06 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sage Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral COMPASS Pathways 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SAGE or CMPS? Sage Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Do analysts prefer SAGE or CMPS? Sage Therapeutics currently has a consensus price target of $12.83, indicating a potential upside of 148.23%. COMPASS Pathways has a consensus price target of $30.67, indicating a potential upside of 595.39%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 2 Sell rating(s) 17 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCOMPASS Pathways beats Sage Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$301.73M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-2.0011.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book1.5610.377.096.50Net Income-$118.46M$153.60M$119.65M$226.22M7 Day Performance-12.50%4.60%2.25%4.03%1 Month Performance-31.52%-6.29%-2.33%4.92%1 Year Performance-27.11%33.41%33.98%29.30% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways2.9186 of 5 stars$4.41-0.9%$30.67+595.4%-27.1%$301.73MN/A-2.00120Positive NewsSAGESage Therapeutics4.3758 of 5 stars$4.85-1.2%$12.83+164.6%-73.4%$296.67M$86.46M-0.90690Analyst ForecastMGNXMacroGenics3.8584 of 5 stars$3.19-2.7%$7.63+138.7%-56.2%$200.44M$58.75M-2.02430RPTXRepare Therapeutics2.3511 of 5 stars$2.97+4.6%$10.00+236.7%-42.4%$126.26M$51.13M-1.49180Gap UpARQTArcutis Biotherapeutics1.7743 of 5 stars$10.31+1.3%$15.50+50.3%+439.4%$1.21B$59.61M-5.84150CALTCalliditas Therapeutics AB (publ)0.2735 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Positive NewsRCKTRocket Pharmaceuticals4.4402 of 5 stars$13.00-0.3%$51.00+292.3%-35.6%$1.19BN/A-4.65240Analyst ForecastAnalyst RevisionANIPANI Pharmaceuticals4.2863 of 5 stars$55.78+1.2%$77.33+38.6%+10.1%$1.17B$486.82M-101.56642Positive NewsARDXArdelyx4.016 of 5 stars$5.14+4.5%$10.42+102.5%+23.2%$1.17B$251.85M-17.15267Insider TradeMESOMesoblast1.2372 of 5 stars$10.18-1.5%$11.50+13.0%+277.2%$1.16B$5.90M0.0080Gap DownAVDLAvadel Pharmaceuticals2.3401 of 5 stars$11.67+8.5%$24.43+109.4%+2.0%$1.12B$27.96M-14.73154 Related Companies and Tools Related Companies SAGE Competitors MGNX Competitors RPTX Competitors ARQT Competitors CALT Competitors RCKT Competitors ANIP Competitors ARDX Competitors MESO Competitors AVDL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMPS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
